Ziltivekimab

6 trials 1 recruiting

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

1 Recruiting

5 Completed trials

3 Sponsors

25 Countries

Phase III

Phase II/III

Phase III: 5 Phase II/III: 1

Oversight events:

5 serious breaches across 2 trials

View oversight register →

Indications tested

Cardiac failure 2 Acute myocardial infarction 1

Sponsors using this IMP

Novo Nordisk A/S 5 Amsterdam UMC Stichting 1 ECRI-trials B.V. 1

All trials

6 total

Effects of ziltivekimab on coronary atherosclerotic burden in patients with acute myocardial infarction Recruiting

2024-520364-34-00 Phase III 5 countries ECRI-trials B.V.; Novo Nordisk A/S
Specifying the Anti-inflammatory Effects of Ziltivekimab (SPIDER) Ended

2024-515893-29-01 Phase II/III 1 country Stichting Amsterdam UMC
ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended

2023-506876-28-00 Phase III 10 countries Novo Nordisk A/S
ATHENA: A research study looking into how ziltivekimab works compared to placebo in people with heart failure and inflammation Ended

2023-506988-34-00 Phase III 7 countries Novo Nordisk A/S
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Phase III 24 countries Novo Nordisk A/S
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended

2023-506926-35-00 Phase III 18 countries Novo Nordisk A/S

Showing 1–6 of 6 trials

← All drugs A–Z